© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Higher Prepregnancy BMI Category Linked to Increase in Poor Maternal and Neonatal Outcomes
May 21, 2024
Women with class 3 obesity before becoming pregnant have up to a 4.5-fold greater risk of composite maternal morbidity that includes preeclampsia, preterm delivery, DM.
Dupilumab in Replicate Phase 3 Trial Significantly Reduces COPD Exacerbations, Improves Lung Function, with PDUFA Date in Sight
May 21, 2024
Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.
Tezepelumab Cuts COPD Exacerbation Rate in High-Risk Population: COURSE Trial Highlights with Dave Singh, MD
May 20, 2024
Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.
Tezepelumab Reduces Rate of COPD Exacerbations in Individuals with Wide Range of Blood Eosinophil Levels: Phase 2a COURSE Trial Findings
May 20, 2024
ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.
ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD
May 20, 2024
The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.
Menopausal VMS Severity, Frequency Reduced Significantly with Elinzanetant: Bayer Shares Data from Pivotal OASIS 1 and 2 Trials
May 17, 2024
The 2 phase 3 trials met all primary and secondary endpoints, showing statistically significant reduction in symptoms and sleep disturbance and improvement in quality of life.
Roche Says Investigational Once-Weekly "Twincretin" Shows Promise in Adults with Obesity in Early Stage Clinical Trial
May 17, 2024
In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.
Lilly's Once-A-Week Insulin Demonstrates Safety, HbA1c Lowering Consistent with Daily Insulin
May 16, 2024
Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups
May 15, 2024
Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.
AstraZeneca at ATS 2024: Look for Late-Breaking Data on Novel Therapeutics for COPD
May 08, 2024
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.